Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Voyager Therapeutics Inc. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 4 examiners and 4 art units, indicating separate examination settings throughout the docket.
SHAH, NILAY J is the busiest examiner, with 1 pending matter. Counsel should maintain consistent biotechnology and pharmaceutical positions while preparing action-specific responses for the separate assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHAH, NILAY J | 1 | 76.3% | +46.9% |
| BURKHART, MICHAEL D | 1 | 62.4% | +11.8% |
| BUTTICE, AUDREY L | 1 | 46.6% | +26.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18810410 | CANNULA SYSTEM AND USE THEREOF | SHAH, NILAY J | — |
| 18693275 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2 POSITIVE CANCER | BUTTICE, AUDREY L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18810410 | CANNULA SYSTEM AND USE THEREOF | SHAH, NILAY J | — |
| 18624753 | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | BURKHART, MICHAEL D | — |
| 18693275 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2 POSITIVE CANCER | BUTTICE, AUDREY L | — |
| Art Unit | Apps |
|---|---|
| 3783 | 1 |
| 1638 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18810410 | CANNULA SYSTEM AND USE THEREOF | SHAH, NILAY J | 3783 | §102§103§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18624753 | AADC POLYNUCLEOTIDES FOR THE TREATMENT OF PARKINSON'S DISEASE | BURKHART, MICHAEL D | 1638 | §103§112DP | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18693275 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2 POSITIVE CANCER | BUTTICE, AUDREY L | 1647 | §103§112 | Non-Final OA | — | Pending | Mar 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVoyager Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Nilay J Shah has the most, with 1 of Voyager Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
